What is Voceryq, the first DNA-based immunotherapy the FDA just approved — and who is it actually for?

On October 30, 2026 the FDA granted accelerated approval to Voceryq (INOVIO's INO-3107), the first plasmid DNA-based immunotherapy approved in the US, to reduce how often adults with recurrent respiratory papillomatosis (RRP) need surgery. The evidence, the limits of accelerated approval, and the rollout timeline — stated plainly, with no cure claim.

Short answer: Voceryq is the brand name for INO-3107, a plasmid DNA-based immunotherapy from INOVIO. On October 30, 2026, the FDA granted it accelerated approval — the first approval of its kind in the United States — to reduce how often adults with recurrent respiratory papillomatosis (RRP) need surgery. RRP is a rare condition in which wart-like growths, caused by HPV types 6 and 11, keep returning in the airways and are removed again and again in the operating room.How it works, in plain terms: Voceryq is given by injection into muscle using INOVIO’s CELLECTRA delivery device.

Instead of attacking the growths directly, the DNA instructions train the patient’s own immune system to recognise and respond to the virus driving them — so the goal is fewer growths returning, and therefore fewer surgeries.What the evidence actually shows:1. Who it is for: adults with RRP — this approval does not cover children, and it is not a treatment for HPV in general.2. The study behind it: an open-label Phase 1/2 study (RRP-001, NCT04398433) enrolled 32 adults, each of whom had needed at least two surgeries in the year before treatment.3.

The headline result: of 26 patients evaluated, 7 — about 27% — needed no surgery at all in the 12 months after treatment.4. The limits, stated plainly: accelerated approval rests on an intermediate endpoint, the study had no control group to compare against, and continued approval depends on a confirmatory study, with a draft protocol due by the end of 2026. Availability is expected about 60 days after approval, with a fuller rollout in early 2027.

This is not a cure, and nobody should read it as one.Pro tip: if you live with RRP, do not wait on headlines — ask your ENT specialist whether you fit the adult indication and what the confirmatory-study timeline means for you.